🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

May the road rise up to meet you. May the wind be always at your back. May the sun shine warm upon your face; the rains fall soft upon your fields and until we meet again, may God hold you in the palm of His hand. Happy #StPatricksDay ☘️

❓Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer 👉🏽 Excellent review of existing data on immune checkpoint inhibitors with efficacy & safety for each oncogene-driven subtype of NSCLC #lcsm OncoAlert

Simultaneous #AACR23 publication in Cancer Discovery from Ferdinandos Skoulidis et al on the largest cohort to date of #KRAS G12C NSCLC treated with sotorasib and adagrasib (n=424). Co-alterations in KEAP1, SMARCA4, CDKN2A poor predictors. Need novel combinations here. aacrjournals.org/cancerdiscover…

FDA approves repotrectinib (Augtyro) for #ROS1 NSCLC based on the phase I/II TRIDENT trial with 1L RR was 79% with mDOR 34.1m and after ROS1 TKI therapy, RR 38% with mDOR 14.8m. Also has activity at #NTRK (which mediates some toxicity). reuters.com/business/healt…

Press release: phase III LAURA trial meets primary endpoint. Stage III #EGFR NSCLC post chemoradiation, indefinite osimertinib superior to placebo. No surprise - eager to see magnitude of benefit, patterns of relapse, OS trends, and crossover rate… astrazeneca.com/media-centre/p…

Press release: phase III ADRIATIC study of durvalumab after chemoradiation for limited stage #SCLC improves both PFS and OS. Follows the PACIFIC approach, randomizing after definitive chemoradiation. Await data on durva + tremelimumab arm. #LCSM astrazeneca.com/media-centre/p…

EVOKE-01 from #ASCO24 Journal of Clinical Oncology. Phase III study of the Trop2 ADC sacituzumab govitecan vs docetaxel in NSCLC post chemo/IO. Did not meet OS endpoint (11.1 vs 9.8m, HR 0.84) but numeric improvement in squamous & non-sq. If nonresponsive to IO, OS HR 0.75 ascopubs.org/doi/10.1200/JC…

CROWN results from #ASCO24 Journal of Clinical Oncology: phase III 1L lorlatinib vs crizotinib in #ALK NSCLC. With 5y median f/u, median PFS not reached. 5y PFS rate 60% with lorlatinib (8% with crizotinib), median time to intracranial progression NR vs 16.4m (HR 0.06). ascopubs.org/doi/10.1200/JC…

KRYSTAL-12: Adagrasib vs Doce in KRAS G12C ✅ ⬆️ PFS HR=0.58 ✅ ⬆️ ORR 32 v 9% ✅ ⬆️ icRR 24 v 11% ❗️29% crossover ❗️⬆️ dose reduction, interruption + SAE 🤔 PFS benefit still modest 🤔 OS should be primary EP 🤔 CNS activity important 🤔 Toxicity significant #ASCO24 #LCSM

Olomorasib (G12Ci) + Pembro, Ph1b ✅ ORR = 77% (1L), 40% (2L+) ✅ Irrespective of PD-L1 🔺 Gr3 AE = diarrhoea (13%), liver (6–8%), pruritis ❓Liver tox shortlived 🤔 Encouraging activity 🤔 Ph3 data needed 🤔 Severe tox in other immuno combos not seen here 👍 #ASCO24 #LCSM

POP QUIZ: Is this a waterfall plot for a new lung cancer TKI? Nope…SEZ6 ADC for Relapsed Small Cell Lung Cancer (and other NECs). #SCLC #LCSM. MD Anderson Cancer Center Thank you to the study team and all of our investigators, patients and families. ASCO #ASCO24

LAURA Trial receives a well deserved huge applause by the audience. Huge benefit in PFS (39 vs 5.6 mo, HR < 0.2. OS still immature and 81% crossover. STAGE III EGFR+ NSCLC INCURABLE? BRAIN RMN BUT NO PET-CT required at baseline. #ASCO24 Lecia Sequist, MD, MPH

#ADRIATIC - new standard of care in #SCLC, where we have not seen an advance in >2 decades. Truly historic data with use of immunotherapy consolidation #LungPlenary David R. Spigel, MD, FASCO Lauren Averett Byers, MD ASCO #ASCO24 OncoAlert

Having seen LAURA, Dr Jayakrishnan presents retrospective ALK+ unresectsble st3 outcomes by consolidation Rx ost. Chemo-RT. ALK TKI rwPFS huge va no consolidation. Translates to OS benefit. Reinforces Lecia Sequist, MD, MPH message that TKI consolidation important for AGA NSCLC #ASCO24

When you’re given a platform, you use it. Women: You can be great mothers and have successful careers. These are not mutually exclusive. Huge thanks to the UCSD Medical School graduating class for inviting me to speak this year! #womeninmedicine

ctDNA+ in consolidation IO trial (BTCRC 16-081) associates with outcomes in stage III unresectable NSCLC JTO & JTO CRR: - Tumor-informed ctDNA MRD analysis post CRT, C2D1 IO, & post 6m of IO - ctDNA+ assoc with ⬇️PFS at all timepts OncoAlert Greg Durm #LCSM jto.org/article/S1556-…

Why do people get ALK+ lung cancer? Why do some respond well to treatments and others less so? How can we better treat this disease? Lung cancer research is not just about answering these key questions, but about hope. It's why Dr @AngelQinMD believes #MoreResearchMoreLife.

Indiana University reception at #ASCO2025 . Proud to work with a fantastic group of past, present, and future colleagues IU Simon Comprehensive Cancer Center Indiana University Hematology/Oncology Fellowship IU_UroOnc Rafat Abonour Christopher Sweeney, MBBS Noah Richardson Robin Zon, MD, FACP, FASCO Ahmad Al-Hader Greg Durm Nasser Hanna Jennifer Schwartz MD FASCO

Dr. Anita Turk discusses Advances in Biomarker Based Management in Mets Colorectal Ca IU Simon Comprehensive Cancer Center Indiana University Hematology/Oncology Fellowship Anita Turk

Dr. Rebecca Hassoun presenting outcomes with salvage high dose chemo and transplant in relapsed GCT based on radiographic vs tumor marker progression Rebecca Hassoun IU Simon Comprehensive Cancer Center Indiana University Hematology/Oncology Fellowship